BMJ1d
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
Correspondence to Dr John H Stone, Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA 02114, USA; jhstone{at}mgh.harvard.edu IgG4-related disease (IgG4-RD) can cause ...
BMJ6d
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...
BMJ5d
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...
BMJ5d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ5d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ5d
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...
BMJ4d
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
3 Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden 4 Department of Nephrology and Transplantation, Skane University Hospital Malmö, Lund University, Sweden Introduction ...
BMJ6d
AB0664 Life expectancy in patient with giant cell arteritis (GCA): impact of vision loss
Background and purpose Several epidemiologic studies reported increased mortality in patients with GCA, while others found that the overall survival was essentially identical to that of the general ...
BMJ5d
Genetics of rheumatoid arthritis: 2018 status
Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...
BMJ2d
POS1130 PHARMACOKINETICS AND SERUM URATE LOWERING EFFECTS OF AR882, A NOVEL, POTENT AND SELECTIVE URICOSURIC AGENT, IN PATIENTS WITH GOUT
Background: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout. In Phase 1 healthy subject studies, ...
BMJ2d
PTPN14 phosphatase and YAP promote TGFβ signalling in rheumatoid synoviocytes
Correspondence to Dr. Nunzio Bottini, Dept. of Medicine, University of California San Diego, MC0656, La Jolla, CA 92093, USA; nbottini{at}ucsd.edu; Professor Costantino Pitzalis, William Harvey ...